What is pathophysiology of Alzheimer?

['Saurari wannan shafin']

Menene ilimin halittar jiki na Alzheimer?

Pathophysiology na cutar Alzheimer (AD) tsari ne mai rikitarwa wanda ya ƙunshi tarin ƙwayoyin cuta, kumburi, da rashin aiki na neuronal.

Manyan alamomin guda biyu na AD sune kasancewar amyloid-beta (Aβ) plaques da neurofibrillary tangles (NFTs) a cikin kwakwalwa.

Amyloid-beta plaques suna samuwa lokacin da enzymes suka yanke sassan furotin na amyloid (APP) don samar da peptides na Aβ.

Wadannan peptides suna haɗuwa kuma suna samar da fibrils marasa narkewa waɗanda ke tarawa a waje da ƙwayoyin cuta, suna lalata sadarwa ta sel zuwa sel kuma suna haifar da mutuwar neuronal.

Tarin Aβ plaques ana tsammanin yana ɗaya daga cikin abubuwan farko a cikin ci gaban AD, kuma an yi imanin yana ba da gudummawa ga tsarin neurodegenerative.

Neurofibrillary tangles suna samuwa lokacin da furotin tau ya zama hyperphosphorylated kuma ya samar da filaments marasa kyau a cikin neurons.

Wadannan tangles suna lalata aikin al'ada na microtubules, waɗanda ke da mahimmanci don jigilar abubuwan gina jiki da sauran kayan cikin neuron.

A ƙarshe, waɗannan ƙwayoyin jijiyoyin suna mutuwa.

Kumburi kuma yana taka rawa a cikin ilimin halittar jiki na AD.

Tsarin garkuwar jiki yana amsa tarin Aβ plaques da NFTs ta hanyar sakin cytokines mai kumburi, wanda zai iya ƙara lalacewar ƙwayoyin cuta.

Bugu da ƙari, akwai shaidar cewa damuwa na oxidative, rashin aiki na mitochondrial, da lalata metabolism na glucose suna ba da gudummawa ga ilimin kimiyyar cutar ta AD.

Waɗannan abubuwan na iya haifar da rashin aiki da mutuwar neuronal, yana ƙara tsananta cutar.

Gabaɗaya, ilimin kimiyyar cututtukan cututtukan AD abu ne mai rikitarwa na abubuwa da yawa waɗanda a ƙarshe ke haifar da ci gaba da raguwa a cikin aikin fahimi da asarar ƙwaƙwalwar da ke nuna cutar.

['Abubuwan da aka ambata']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Bayanin sanarwa: likita']

['Wannan shafin yanar gizon don ilimantarwa ne kawai ba don ba da shawara ko kuma ba da shawara ta likita ba.']

['Bai kamata a yi amfani da bayanin da aka bayar don gano ko magance matsalar lafiya ko cuta ba, kuma waɗanda suke neman shawarar likita na sirri ya kamata su tuntuɓi likitan da ke da lasisi.']

['Lura cewa hanyar sadarwar jijiyoyin da ke samar da amsoshin tambayoyin, ba ta da daidaito musamman idan ya zo ga abun cikin lamba. Misali, yawan mutanen da aka gano suna da takamaiman cuta.']

["Koyaushe nemi shawarar likitanka ko wani ƙwararren mai ba da lafiya game da yanayin likita. Kada ka taɓa yin watsi da shawarar likita ko jinkiri wajen neman ta saboda wani abu da ka karanta a wannan rukunin yanar gizon. Idan kuna tsammanin kuna da matsalar gaggawa ta likita, kira 911 ko je zuwa ɗakin gaggawa mafi kusa nan da nan. Babu wata alaƙar likita da mara lafiya da aka ƙirƙira ta wannan rukunin yanar gizon ko amfaninsa. BioMedLib ko ma'aikatanta, ko kowane mai ba da gudummawa ga wannan rukunin yanar gizon, ba su yin kowane wakilci, bayyane ko a bayyane, dangane da bayanan da aka bayar a nan ko amfaninsa."]

['Bayanin haƙƙin mallaka']

['Dokar haƙƙin mallaka ta Millennium ta 1998, 17 U.S.C. § 512 (DMCA) tana ba da damar neman masu haƙƙin mallaka waɗanda suka yi imanin cewa kayan da ke bayyana a Intanet sun keta haƙƙinsu a ƙarƙashin dokar haƙƙin mallaka ta Amurka. ']

['Idan kun yi imani da gaskiya cewa duk wani abun ciki ko kayan da aka samar dangane da gidan yanar gizon mu ko ayyukanmu ya keta haƙƙin mallaka, ku (ko wakilin ku) na iya aiko mana da sanarwa don neman cire abun ciki ko kayan, ko toshe damar zuwa gare shi. ']

["Dole ne a aika da sanarwa a rubuce ta hanyar imel (duba sashin 'Saduwa' don adireshin imel). "]

['DMCA tana buƙatar sanarwar ku game da zargin keta haƙƙin mallaka ya haɗa da waɗannan bayanan: (1) bayanin aikin haƙƙin mallaka wanda shine batun zargin cin zarafin; (2) bayanin abin da ake zargi da cin zarafin abun ciki da kuma isasshen bayani don ba mu damar gano abun ciki; (3) bayanin tuntuɓar ku, gami da adireshin ku, lambar tarho da adireshin imel; (4) sanarwa daga gare ku cewa kuna da kyakkyawan imani cewa abun cikin yadda ake korafin ba shi da izinin mai haƙƙin mallaka, ko wakilinsa, ko ta aikin kowace doka; ']

['(5) sanarwa daga gare ku, wanda aka sanya hannu a ƙarƙashin hukuncin shaidar zur, cewa bayanin da ke cikin sanarwar daidai ne kuma kuna da ikon aiwatar da haƙƙin mallaka wanda ake zargin an keta shi; ']

['da (6) sa hannu na zahiri ko na lantarki na mai haƙƙin mallaka ko mutumin da aka ba shi izinin yin aiki a madadin mai haƙƙin mallaka. ']

['Rashin hada dukkan bayanan da ke sama na iya haifar da jinkiri wajen aiwatar da korafin ka.']

['Tuntuɓi']

['Da fatan za a aiko mana da imel tare da kowace tambaya / shawara.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['Game da']

["BioMedLib yana amfani da kwamfutoci na atomatik (algorithms na koyon inji) don samar da nau'ikan tambaya da amsa."]

['Mun fara da wallafe-wallafen likitancin halittu miliyan 35 na PubMed/Medline. Har ila yau, shafukan yanar gizo na RefinedWeb.']

['Duba "Magana" kuma "Sakin sanarwa".']